Aurinia Pharmaceuticals (AUPH) stock plummeted 13.46% in the pre-market trading session on Thursday, following the release of the company's fourth-quarter 2024 earnings report and forward guidance.
Despite reporting better-than-expected Q4 earnings and revenue, with EPS of $0.01 beating analyst estimates of a $0.02 loss and revenue of $59.87 million exceeding forecasts of $59.7 million, investors were seemingly unimpressed with the company's performance.
While Aurinia swung to a full-year 2024 profit of $5.8 million after reporting a loss in the previous year, the company's forward guidance for 2025 revenue of $250-$260 million appears to have fallen short of market expectations, potentially triggering the sharp sell-off.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.